ALLMedicine™ Antithrombin Deficiency Center

Mar 16th, 2021 - Hereditary antithrombin (AT) deficiency is an autosomal dominant thrombophilic disorder. Guidelines do not support routine testing of children based on personal or familial thrombosis. To investigate clinical, genetic and laboratory profiles of AT...

Feb 2nd, 2021 - Anticoagulation in extracorporeal membrane oxygenation (ECMO) is challenging, with significant morbidity and mortality associated with thrombotic complications. Unfractionated heparin (UFH) is commonly used, which depends on native antithrombin (A...

Nov 16th, 2020 - o explore the phenotype and genotype of a hereditary antithrombin deficient Chinese family. Functional and molecular analysis of the proband and his family members was performed. Online bioinformatics software was used to predict the pathogenicity...

Oct 26th, 2020 - To summarize the literature assessing the safety and efficacy of direct oral anticoagulants (DOACs) for the acute treatment and secondary prevention of venous thromboembolism (VTE) in select patients with hypercoagulable disorders. An electronic P...

Sep 13th, 2020 - Hereditary antithrombin deficiency is a rare autosomal-dominant disorder predisposing to recurrent venous thromboembolism (VTE). To date, only two founder mutations have been described. We investigated the antithrombin p.Thr147Ala variant, found i...

Mar 16th, 2021 - Hereditary antithrombin (AT) deficiency is an autosomal dominant thrombophilic disorder. Guidelines do not support routine testing of children based on personal or familial thrombosis. To investigate clinical, genetic and laboratory profiles of AT...

Feb 2nd, 2021 - Anticoagulation in extracorporeal membrane oxygenation (ECMO) is challenging, with significant morbidity and mortality associated with thrombotic complications. Unfractionated heparin (UFH) is commonly used, which depends on native antithrombin (A...

Nov 16th, 2020 - o explore the phenotype and genotype of a hereditary antithrombin deficient Chinese family. Functional and molecular analysis of the proband and his family members was performed. Online bioinformatics software was used to predict the pathogenicity...

Oct 26th, 2020 - To summarize the literature assessing the safety and efficacy of direct oral anticoagulants (DOACs) for the acute treatment and secondary prevention of venous thromboembolism (VTE) in select patients with hypercoagulable disorders. An electronic P...

Sep 13th, 2020 - Hereditary antithrombin deficiency is a rare autosomal-dominant disorder predisposing to recurrent venous thromboembolism (VTE). To date, only two founder mutations have been described. We investigated the antithrombin p.Thr147Ala variant, found i...

Oct 27th, 2017 - Absolute risk of pregnancy-associated venous thromboembolism (VTE) varied depending on the type of thrombophilia among women with a family history of VTE, a systematic review and meta-analysis found. While all thrombophilias increased the risk of ...

Dec 20th, 2007 - December 21, 2007 -- The US Food and Drug Administration (FDA) has granted orphan drug designation to CDX-110 for the treatment of glioblastoma multiforme, ATryn for the treatment of hereditary antithrombin deficiency, and ISIS 333611 for the trea...

Fast Track Women with a thrombophilic deficiency who used OCs developed VTE at a younger age than their non–OC-using counterparts A. No.